DBV Technologies S.A.

Good day and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. And to withdraw your question, please press star then two. Thank you. This afternoon, DBV Technologies issued a press release that outlines our financial results for the 12 months ended December 31st, 2022.

This press release is available in the press release section of the DBV Technologies website. Before we begin, please note that today's call may include a number of forward-looking statements, including but not limited to comments regarding our clinical and regulatory development plans, the timing and results of interactions with regulatory agencies, our forecast of our cash runway, and the ability of our product candidates to improve the lives of patients with food allergies. These forward looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward looking statements. Please refer to the company's filings with the SEC and the French AMF for information concerning risk factors that could cause the company's actual results to differ materially from expectations, including any forward looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call. Joining me on today's call are Daniel Tassé, Chief Executive Officer of DBV, Sebastian Rogatay, Chief Financial Officer, and Pharis Mohideen, Chief Medical Officer. I will now pass the call over to Daniel. Daniel?

And thank you and thank you all for joining us on this call this afternoon. In a few moments, Sébastien will walk you through the highlights of the full year 2022 financial results. But before he does that, I'd like to take a few moments to talk about recent clinical updates. Last year, our top priority was to finalize the design and protocol of VITESS The Phase 3 Pivotal Study of the Modified Bioskin Peanut Patch in Children Ages 4 to 7 with a Confirmed Peanut Allergy Diagnosis. We did that, and we are on track to screen our first patient by the end of the first quarter this year, and we look forward to providing an update when this event occurs. Now, in advance of initiating the test, we completed a study called EVOLVE, which was a 12-week caregiver and patient user experience study with the modified viaskin peanut patch in 50 peanut allergic children ages 4 to 11 years of age. Now, our objective with Evolve was pretty straightforward. It was to optimize the e-diary tool that families will use in vitess to best capture patch adhesion and patch experience data. I will invite Pharis to speak in more detail about Evolve, what we learned from it, as well as also update you all on Viascantina data that was presented last weekend at the American Academy of Allergy, Asthma, Immunology annual scientific meeting, the meeting that we all know as Quad AI. Pharis?